Список литературы

1. Давыдов М.И., Полоцкий Б.Е. Рак легкого - М: Радикс, 1994, 206 стр.

2. Трахтенберг А.Х., Чиссов В.И. Клиническая онколопульмонология - М.,

3. The Health Consequences of Smoking: A Report of the Surgeon General (ed 2010/07/30). Atlanta (GA): U.S. Department of Health and Human Services. Centers for Disease Controland Prevention (US) 2004

4. Goldstraw P. Staging Manual in Thoracic Oncology. An International Association for the Study of Lung Cancer Publication, 2009.

5. Fossella FV, Putnam JB, Komaki R., eds. Lung Cancer. M.D. Andersen Cancer Care Serires. New York: Springer; 2003: 316

6. Schrump DS, Carter D, Kelsey CR, et al. Non-small cell lung cancer. In DeVita Jr. VT, LawrenceTS, Rosenberg SA, et al., eds. DeVita, Heilman, and Rosenberg Cancer; Prinsiples and Practice of Oncology. Philadelphia; Lippincott Williams and Wilkins; 2011

7. Аллахвердиев А.К., Давыдов М.М. Торакоскопическая лобэктомия с медиастинальной лимфодиссекцией стандарт в хирургическом лечении больных немелкоклеточным раком легкого T1 - 2N0M0//Вопр. онкол. 2015 - Т. 61, N 3, стр. 413 - 417

8. Gopaldas R.R., Bakaeen F.G., Dao T.K. et al. Video-assisted thoracoscopic versus open thoracotomy lobectomy in a cohort of 13619 patients//Ann. Thorac. Surg. - 2010. - Vol. 89, N 5. - P. 1563 - 1570

9. Higuchi M., Yaginuma H., Yonechi A. et al. Long-term outcomes after video-assisted thoracic surgery (VATS) lobectomy versus lobectomy via open thoracotomy for clinical stage Ia non-small cell lung cancer//J. Cardiothorac. Surg. - 2014. - Vol. 9. - P. 88 - 92

10. Naruke T. Lymph node metastasis of lung cancer and associated surgery//Asian Medical Journal, 1990, v. 33, N 12, h. 668 - 677.

11. Paul S., Altorki N.K., Sheng S. et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS Database//J. Thorac. Cardiovasc. Surg. - 2010 - Vol. 139. - P. 366 - 378

12. Scott W.J., Allen M.S., Darling G. et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Sugeons Oncology Group Z0030 randomised clinical trial//J. Thorac. Cardiovasc. Surg. - 2010. - Vol. 139. - P. 976 - 981.

13. Ginsberg R.J., Rubinstein L.V. Randomised trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer//Ann. Thorac. Surg. - 1995. - Vol. 60. - P. 615 - 622

14. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med 2004; 350: 351 - 360/

15. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N. Engl. J. Med 2005; 352: 2589 - 2597

16. Douillard J.Y, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (ANITA): a randomized controlled trial. Lancet Oncol. 2006: 7: 719 - 727.

17. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperativw cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J. Clin. Oncol. 2012; 30: 172 - 178.

18. Curran WJ, Paulus R, Langer CJ, et al. Sequential vs concurrent chemoradiation for stage III non-small-cell lung cancer randomized phase III trial RTOG 9410. J. Natl. Cancer Inst 2011; 103: 1452 - 1460.

19. Masters GA, Temin S, Azzoli CG, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer. American Society of Clinical Oncology. Clinical Practice Guideline Update. J Clin Oncol 2015; 33: 3488 - 3515

20. Burroto M, Manasanch EE, Wilkerson J, Fojo T. Gefitinib and erlotinib in metastatic non-small-cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 2015; 20: 400 - 410

21. Sequst LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol; 2013: 31: 3327 - 3334.

22. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart 2015

23. Solomon BJ, Mok T, Kim DW et al. First-line crisotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med 2013; 371: 2167 - 2177

24. Costa DB, Shaw AT, Ou SH et al. Clinical Experience With Crisotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin. Oncol. 2015; 33: 1881 - 1888

25. Camidge DR, Bang YU, Kwak EL., et al. Activity and safety of crisotinib in patients with ALK-positive non-small-cell lung cancer, updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011 - 1019

26. Shaw AT, Yeap BY, Solomon BJ et al. Impact of crisotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls [abstract] J Clin. Oncol 2011; 29 (Suppl 15): Abstract 7507

27. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol 2008; 26: 3543 - 3551

28. D Addario G, Pintile M, Leighi NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of published literature. J. Clin. Oncol 2005; 23: 2926 - 2936

29. :Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599of bevacisumab with paclitaxel/carboplatin for advanced non-small-cell lung cancer. J. Thorac. Oncol. 2010; 5: 1416 - 1423

30. Azzoli cG, Temin S, Aliff T, et al. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update of Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2011; 29: 3825 - 3831

31. Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 2013; 31: 4349 - 4357

32. Perol M, Chouaid C, Perol D et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2012; 30: 3516 - 3524

33. Besse B, Adjei A, Baas P, et al. 2^nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line\second and futher lines of treatment in advanced disease. Ann. Oncol. 2914; 25: 1475 - 1484

34. Sheperd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 2000; 18: 2095 - 2103

35. Hanna N, Sheperd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004; 22: 1589 - 1597

36. Sculier JP, Lafitte JJ, Berghmans T et. al. A phase II trial testing gemcitabine as second-line chemotherapy for non-small-cell lung cancer. The European Lung Cancer Working Party Lung Cancer 2000; 29: 67 - 73

37. Sheperd FA, Rodrigues Pereira J, Cuileanu T, et. al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med 2005; 353: 132 - 132.

38. Reck M, Rodrigues-Abreu D, Robinson AG, et al. Pembrolisumab versus chemotherapy for PD-1-positive non-small-cell lung cancer. N. Engl. J. Med 2016; 375: 1823 - 1833

39. Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary nivolumab for the treatment of metastatic non-small-cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist 2016, 21: 634 - 642

40. Borghaei H, Paz-Ares L, Horn 1, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N. Eng1. J. Med. 2015; 373: 1627 - 1639.

41. Schreiber D, Rineer J, Weedon J, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer. 2010 Mar l; 116(5): 1350 - 7. (http://www.ncbi.nlm.nih.gov/pubmed/20082453)

42. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006; 17: 543 - 52. (http://www.ncbi.nlm.nih.gov/pubmed/20082453)

43. Zatloukal P, (http://www.ncbi.nlm.nih.gov/pubmed/? term=Zatloukal%20P%5BAuthor%5D&cauthor=true&cauthor_uid=20231298)Cardenal F, (http://www.ncbi.nlm.nih.gov/pubmed/? term=Cardenal%20F%5BAuthor%5D&cauthor=true&cauthor_uid=20231298)Szczesna A, et al A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease (http://www.ncbi.nlm.nih.gov/pubmed/? term=Szczesna%20A%5BAuthor%5D&cauthor=true&cauthor_uid=20231298)Ann Oncol. 2010 Sep; 21(9): 1810 - 6. (http://www.ncbi.nlm.nih.gov/pubmed/?term=ed+sclc+etoposide+gorbunova)

44. Slotman, BJ, van Tinteren, H, Praag, JO et al. Use of thoracic radiotherapy for extensive stage small cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015; 385: 36 - 42 (http://www.ncbi.nlm.nih.gov/pubmed/?term=ed+sclc+etoposide+gorbunova)

45. Slotman B, (http://www.ncbi.nlm.nih.gov/pubmed/? term=Slotman%20B%5BAuthor%5D&cauthor=true&cauthor_uid=17699816)Faivre-Finn C, (http://www.ncbi.nlm.nih.gov/pubmed/?term=Faivre-Finn%20C%5BAuthor%5D&cauthor=true&cauthor_uid=17699816)Kramer G, et al; (http://www.ncbi.nlm.nih.gov/pubmed/?term=Kramer%20G%5BAuthor%5D&cauthor=true&cauthor_uid=17699816)EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. (http://www.ncbi.nlm.nih.gov/pubmed/?term=EORTC%20Radiation%200ncology%20Group%20and%20Lung%20Cancer%20Group%5BCorporate%20Author%5D)N Engl J Med. 2007 Aug 16; 357(7): 664 - 72. (http://www.ncbi.nlm.nih.gov/pubmed/17699816)

46. Van Der Linden Y.M., Van Kempen M.L., Van Der Tweel I., et al Prophylactic cranial irradiation in limited disease small-cell lung cancer in complete remission: a retrospective analysis. Respiratory Medicine.Volume 95, Issue 3, March 2001, Pages 235 - 236 (http://www.ncbi.nlm.nih.gov/pubmed/17699816)

47. O"Brien ME, Ciuleanu TE, Tsekov H, et al (http://www.ncbi.nlm.nih.gov/pubmed/17699816)Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006 Dec 1; 24(34): 5441 - 7. (http://www.ncbi.nlm.nih.gov/pubmed/17135646)

48. von Pawel J, (https://www.ncbi.nlm.nih.gov/pubmed/? term=von%20Pawel%20J%5BAuthor%5D&cauthor=true&cauthor_uid=10080612)Schiller JH, (https://www.ncbi.nlm.nih.gov/pubmed/? term=Schiller%20JH%5BAuthor%5D&cauthor=true&cauthor_uid=10080612)Shepherd FA, (https://www.ncbi.nlm.nih.gov/pubmed/? term=Shepherd%20FA%5BAuthor%5D&cauthor=true&cauthor_uid=10080612)Fields SZ Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. (https://www.ncbi.nlm.nih.gov/pubmed/? term=Fields%20SZ%5BAuthor%5D&cauthor=true&cauthor_uid=10080612)J Clin Oncol. 1999 Feb; 17(2): 658 - 67. (https://www.ncbi.nlm.nih.gov/pubmed/10080612) (https://www.ncbi.nlm.nih.gov/pubmed/10080612)